Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
12.56
-0.24 (-1.88%)
Feb 21, 2025, 4:00 PM EST - Market closed
Inhibrx Biosciences Employees
As of December 31, 2023, Inhibrx Biosciences had 172 total employees, including 166 full-time and 6 part-time employees.
Employees
172
Change
n/a
Growth
n/a
Revenue / Employee
$9,116
Profits / Employee
$10,047,849
Market Cap
181.82M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 172 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
INBX News
- 4 weeks ago - Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer - PRNewsWire
- 5 weeks ago - Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - PRNewsWire
- 3 months ago - Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PRNewsWire
- 3 months ago - Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha
- 3 months ago - Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - PRNewsWire
- 6 months ago - Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying - Benzinga
- 6 months ago - Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - PRNewsWire
- 9 months ago - Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi - Seeking Alpha